Detalhe da pesquisa
1.
Efficacy and safety of luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndromes (COMMANDS): interim analysis of a phase 3, open-label, randomised controlled trial.
Lancet
; 402(10399): 373-385, 2023 07 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-37311468
2.
Luspatercept stimulates erythropoiesis, increases iron utilization, and redistributes body iron in transfusion-dependent thalassemia.
Am J Hematol
; 99(2): 182-192, 2024 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-37782758
3.
A Phase 3 Trial of Luspatercept in Patients with Transfusion-Dependent ß-Thalassemia.
N Engl J Med
; 382(13): 1219-1231, 2020 03 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-32212518
4.
Health-related quality of life in patients with ß-thalassemia: Data from the phase 3 BELIEVE trial of luspatercept.
Eur J Haematol
; 111(1): 113-124, 2023 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-37095595
5.
Longer-term benefit of luspatercept in transfusion-dependent lower-risk myelodysplastic syndromes with ring sideroblasts.
Blood
; 140(20): 2170-2174, 2022 11 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-35797468
6.
Barriers and Enablers for Physical Activity Engagement Among Individuals From India With Type 2 Diabetes Mellitus: A Mixed-Method Study.
J Phys Act Health
; 21(5): 519-527, 2024 May 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-38402875
7.
Psychometric evaluation of the NTDT-PRO questionnaire for assessing symptoms in patients with non-transfusion-dependent beta-thalassaemia.
BMJ Open
; 13(3): e066683, 2023 03 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-36948565
8.
Receptor for Advanced Glycation End Product, Organ Crosstalk, and Pathomechanism Targets for Comprehensive Molecular Therapeutics in Diabetic Ischemic Stroke.
Biomolecules
; 12(11)2022 11 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-36421725
9.
Long-term safety and erythroid response with luspatercept treatment in patients with ß-thalassemia.
Ther Adv Hematol
; 13: 20406207221134404, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-36505885
10.
Long-Term Efficacy and Safety of Luspatercept for Anemia Treatment in Patients With Lower-Risk Myelodysplastic Syndromes: The Phase II PACE-MDS Study.
J Clin Oncol
; 40(33): 3800-3807, 2022 11 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-35998303
11.
Luspatercept for the treatment of anaemia in non-transfusion-dependent ß-thalassaemia (BEYOND): a phase 2, randomised, double-blind, multicentre, placebo-controlled trial.
Lancet Haematol
; 9(10): e733-e744, 2022 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-36007538
12.
Health-Related Quality of Life Outcomes in Patients with Myelodysplastic Syndromes with Ring Sideroblasts Treated with Luspatercept in the MEDALIST Phase 3 Trial.
J Clin Med
; 11(1)2021 Dec 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-35011768
13.
Relationship between free iron and glycated hemoglobin in uncontrolled type 2 diabetes patients associated with complications.
Indian J Clin Biochem
; 23(1): 67-70, 2008 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-23105724
14.
Urinary protein thiols in different grades of proteinuria.
Indian J Clin Biochem
; 23(4): 404-6, 2008 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-23105797
15.
Iron supplementation and oxidative stress in patients with uremia.
Indian J Physiol Pharmacol
; 51(2): 179-82, 2007.
Artigo
em Inglês
| MEDLINE | ID: mdl-18175664
16.
Luspatercept for myelodysplastic syndromes/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis.
Leukemia
; 36(5): 1432-1435, 2022 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-35220402
17.
Bisalbuminemia in a Hypothyroid Patient with Diabetes: A Case Report.
J Clin Diagn Res
; 9(9): BD01-2, 2015 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-26500899
18.
Serum paraoxonase in alcohol abusers associated with alcoholic liver disease.
Clin Chim Acta
; 378(1-2): 232-4, 2007 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-17258183
19.
Bisalbuminemia in an adult male with Alzheimer's disease.
Indian J Med Sci
; 61(6): 356-7, 2007 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-17558099